查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1594648

開放性青光眼治療藥物市場：按產品、藥物類別、分銷管道、最終用戶 - 全球預測 2025-2030

Open-Angle Glaucoma Therapeutics Market by Product (Non-PGAs, PGAs), Drug Class (Bimatoprost, Latanoprost, Travoprost), Distribution Channel, End Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年開放性青光眼治療市值為86.4億美元，預計2024年將達到93.5億美元，複合年成長率為8.74%，到2030年將達到155.3億美元，預計將達到1000萬美元。

開放性青光眼藥物是指旨在降低眼內壓的治療方法，以防止視神經損傷，從而導致不可逆的視力喪失。該市場包括各種醫療干預措施，如琴酒類似物、 BETA阻斷劑、α促效劑、碳酸酐酶抑制劑、Rho 激酶抑制劑和聯合用藥。需要這些治療是因為這種疾病作為最常見的青光眼形式，特別是在老年族群中，早期診斷和有效的治療對於維持生活品質至關重要。這些治療劑用於醫院、眼科診所和研發機構，對於持續的患者護理和新治療方法的開發至關重要。醫療保健意識的提高和人口老化仍然是關鍵的成長動力，而藥物配方的進步正在提高療效和患者依從性。新的商機在於緩釋性藥物輸送系統和個人化醫療方法的開發，這些方法有望提供最佳化和個人化的治療方法。我們鼓勵製藥公司和研究機構之間建立合作夥伴關係，以加速創新。

主要市場統計
基準年[2023] 86.4億美元
預測年份 [2024] 93.5億美元
預測年份 [2030] 155.3億美元
複合年成長率（%） 8.74%

然而，該市場受到嚴格的法規核准、開拓新藥的高成本以及來自手術和雷射療法等替代療法的競爭的核准。此外，由於疾病的無症狀性以及與長期用藥相關的副作用，患者的依從性仍然是一個挑戰。解決這些問題的努力包括開發具有成本效益和患者友好的配方，並投資於患者教育計劃以提高依從性。市場的創新優勢在於探索神經保護策略和基因治療方案，不僅可以降低眼壓，還可以保護視神經。隨著競爭格局的演變，維持對監管變化和技術整合的反應對於保持競爭優勢至關重要。

市場動態：揭示快速發展的開放性青光眼藥物市場的關鍵市場洞察

供需的動態交互作用正在改變開放性青光眼藥物市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球青光眼盛行率上升
    • 對燃燒劑的需求增加
    • 改進青光眼診斷工具
  • 市場限制因素
    • 青光眼治療藥物召回增加
  • 市場機會
    • 擴大開放性青光眼治療藥物的核准
    • 越來越多引進先進的開放性青光眼治療方法
  • 市場挑戰
    • 缺乏經驗豐富的眼科醫生

波特五力：駕馭開放性青光眼藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解開放性青光眼治療市場的外在影響

外部宏觀環境因素在塑造開放性青光眼治療藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助企業預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解開放性青光眼治療市場的競爭狀況

開放性青光眼治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣開放性青光眼治療市場供應商績效評估

FPNV定位矩陣是評估開放性青光眼治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪開放性青光眼治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，開放性青光眼治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球青光眼發生率上升
      • 對燃燒化學品的需求增加
      • 改進青光眼診斷工具
    • 抑制因素
      • 青光眼治療藥物召回增加
    • 機會
      • 開放性青光眼藥物的核准增加
      • 增加對先進開放性青光眼治療方法的介紹
    • 任務
      • 缺乏經驗豐富的眼科醫生
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章開放性青光眼治療藥物市場：依產品

  • 非PGA
  • PGA

第7章依藥物類別分類的開放性青光眼治療藥物市場

  • Bimatoprost
  • 拉坦前列素
  • 曲伏前列素
  • 烏諾前列酮

第8章開放性青光眼治療藥物市場：按分銷管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第9章開放性青光眼治療藥物市場：依最終使用者分類

  • 門診手術中心
  • 醫院
  • 眼科診所

第10章 北美和南美開放性青光眼治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太開放性青光眼治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的開放性青光眼治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Alcon Inc.
  • Bausch Health Co. Inc.
  • D.Western Therapeutics Institute Inc
  • EyePoint Pharmaceuticals, Inc.
  • Fera Pharmaceuticals
  • Hikma Pharmaceuticals PLC
  • Iridex Corporation
  • Laboratories Sophia
  • Merck and Co. Inc.
  • Nicox SA
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-957C47F9384B

The Open-Angle Glaucoma Therapeutics Market was valued at USD 8.64 billion in 2023, expected to reach USD 9.35 billion in 2024, and is projected to grow at a CAGR of 8.74%, to USD 15.53 billion by 2030.

Open-angle glaucoma therapeutics refer to the treatments aimed at lowering intraocular pressure to prevent damage to the optic nerve, which can lead to irreversible vision loss. This market encompasses a variety of medical interventions, including prostaglandin analogs, beta blockers, alpha agonists, carbonic anhydrase inhibitors, rho kinase inhibitors, and combination drugs. The necessity of these treatments stems from the disease's prevalence as the most common form of glaucoma, particularly affecting older populations where early diagnosis and effective management are crucial to maintaining quality of life. Application settings include hospitals, ophthalmology clinics, and research institutions, where these therapeutics are integral to both ongoing patient care and novel treatment development. Increased healthcare awareness and a growing aging demographic persist as key growth drivers, while advancements in drug formulations enhance efficacy and patient compliance. Emerging opportunities lie in the development of sustained-release drug delivery systems and personalized medicine approaches that promise optimized, individualized treatment regimens. Collaborative partnerships between pharmaceutical companies and research institutes are advised to accelerate innovation.

KEY MARKET STATISTICS
Base Year [2023] USD 8.64 billion
Estimated Year [2024] USD 9.35 billion
Forecast Year [2030] USD 15.53 billion
CAGR (%) 8.74%

Yet, the market encounters limitations such as stringent regulatory approvals, high costs of new drug development, and competition from alternative therapies such as surgery or laser treatments. Additionally, patient adherence remains a challenge due to the asymptomatic nature of the disease and side effects of long-term drug use. Efforts to address these include creating cost-effective, patient-friendly formulations and investing in patient education programs to increase compliance. The market's innovative edge lies in targeting neuroprotective strategies that could protect the optic nerve beyond just lowering intraocular pressure, as well as exploring gene therapy options. As the landscape evolves, staying attuned to regulatory changes and technology integration will be pivotal for maintaining a competitive advantage in the open-angle glaucoma therapeutics market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Open-Angle Glaucoma Therapeutics Market

The Open-Angle Glaucoma Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of glaucoma globally
    • Increasing demand for combustion drugs
    • Improving diagnostic tools to detect glaucoma
  • Market Restraints
    • Rising drug recalls for glaucoma treatments
  • Market Opportunities
    • Growing approvals for open-angle glaucoma therapies
    • Rising introduction of advanced open-angle glaucoma therapies
  • Market Challenges
    • Lack of experienced ophthalmologists

Porter's Five Forces: A Strategic Tool for Navigating the Open-Angle Glaucoma Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Open-Angle Glaucoma Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Open-Angle Glaucoma Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Open-Angle Glaucoma Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Open-Angle Glaucoma Therapeutics Market

A detailed market share analysis in the Open-Angle Glaucoma Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Open-Angle Glaucoma Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Open-Angle Glaucoma Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Open-Angle Glaucoma Therapeutics Market

A strategic analysis of the Open-Angle Glaucoma Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Open-Angle Glaucoma Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alcon Inc., Bausch Health Co. Inc., D.Western Therapeutics Institute Inc, EyePoint Pharmaceuticals, Inc., Fera Pharmaceuticals, Hikma Pharmaceuticals PLC, Iridex Corporation, Laboratories Sophia, Merck and Co. Inc., Nicox SA, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Open-Angle Glaucoma Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Non-PGAs and PGAs.
  • Based on Drug Class, market is studied across Bimatoprost, Latanoprost, Travoprost, and Unoprostone.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
  • Based on End Users, market is studied across Ambulatory Surgical Centers, Hospitals, and Ophthalmic Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of glaucoma globally
      • 5.1.1.2. Increasing demand for combustion drugs
      • 5.1.1.3. Improving diagnostic tools to detect glaucoma
    • 5.1.2. Restraints
      • 5.1.2.1. Rising drug recalls for glaucoma treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing approvals for open-angle glaucoma therapies
      • 5.1.3.2. Rising introduction of advanced open-angle glaucoma therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of experienced ophthalmologists
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Open-Angle Glaucoma Therapeutics Market, by Product

  • 6.1. Introduction
  • 6.2. Non-PGAs
  • 6.3. PGAs

7. Open-Angle Glaucoma Therapeutics Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Bimatoprost
  • 7.3. Latanoprost
  • 7.4. Travoprost
  • 7.5. Unoprostone

8. Open-Angle Glaucoma Therapeutics Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. Open-Angle Glaucoma Therapeutics Market, by End Users

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Hospitals
  • 9.4. Ophthalmic Clinics

10. Americas Open-Angle Glaucoma Therapeutics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Open-Angle Glaucoma Therapeutics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Open-Angle Glaucoma Therapeutics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alcon Inc.
  • 3. Bausch Health Co. Inc.
  • 4. D.Western Therapeutics Institute Inc
  • 5. EyePoint Pharmaceuticals, Inc.
  • 6. Fera Pharmaceuticals
  • 7. Hikma Pharmaceuticals PLC
  • 8. Iridex Corporation
  • 9. Laboratories Sophia
  • 10. Merck and Co. Inc.
  • 11. Nicox SA
  • 12. Novartis AG
  • 13. Pfizer Inc.
  • 14. Sun Pharmaceutical Industries Ltd.
  • 15. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY NON-PGAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PGAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BIMATOPROST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY LATANOPROST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TRAVOPROST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY UNOPROSTONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 191. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023